Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rheumatoid factor revisited.

Thomas Dörner1, Karl Egerer, Eugen Feist

  • 1Department of Medicine/Division of Rheumatology, Ludwigs-Maximilian University Munich, Pettenkoferstrasse 8a, D-80336 Munich, Germany. thomas.doerner@med.uni-muenchen.de

Current Opinion in Rheumatology
|April 23, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Introducing EULAR Rheumatology Open (ERO): A New Platform for Advancing Rheumatology Research.

EULAR rheumatology open·2026
Same author

Comparison of the PK, PD, safety, tolerability, and immunogenicity of proposed biosimilar RGB-19 and tocilizumab in healthy Japanese males: a phase 1, randomised, crossover study.

EULAR rheumatology open·2026
Same author

Efficacy, safety, and immunogenicity of proposed biosimilar RGB-19 and tocilizumab intravenously administered to adults with active rheumatoid arthritis and an inadequate response to methotrexate: a phase 3, randomised study.

EULAR rheumatology open·2026
Same author

Long-term remission and monocyclic course in Still's disease patients starting canakinumab early: data from the international AIDA network registry.

Seminars in arthritis and rheumatism·2026
Same author

Zeitschrift fur Rheumatologie·2026
Same author

Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials).

Rheumatology and therapy·2026

Humoral immunity, particularly rheumatoid factor production, is crucial in rheumatoid arthritis pathogenesis. B cell activation and genetic factors drive this autoimmune response, indicating severe disease and guiding B cell depletion therapies.

Area of Science:

  • Immunology
  • Rheumatology

Background:

  • Early rheumatoid arthritis (RA) research focused on immune complexes and synovitis.
  • Later studies identified T cell responses, cytokines, and chemokines in RA pathogenesis.
  • Recent work highlights the significant role of humoral immunity in RA.

Purpose of the Study:

  • To review recent insights into humoral autoimmunity in rheumatoid arthritis.
  • To discuss the generation and role of rheumatoid factors (RFs).
  • To explore B cell activation, genetic predispositions, and lymphomagenesis in RA.

Main Methods:

  • Review of recent literature on humoral immunity in rheumatoid arthritis.
  • Analysis of antibody discoveries (anti-CCP, anti-RA33, anti-GPI).
  • Discussion of B cell activation via toll-like receptors and genetic factors.

Related Experiment Videos

Main Results:

  • Discovery of specific autoantibodies (anti-CCP, anti-RA33, anti-GPI) has renewed interest in humoral autoimmunity in RA.
  • RF generation is linked to genetic predispositions and immune reaction intensity, seen in RA and other conditions.
  • B cell activation, potentially via toll-like receptors, plays a key role in RF induction.

Conclusions:

  • Rheumatoid factor induction in RA patients signifies severe disease with substantial B cell involvement.
  • B cell depletion therapies show promise, supporting the critical role of humoral immunity in RA progression.